Table 2.
Characteristics of individual patients from DIRA studies included in the review (cont.)
| DIRA patient | Anti-IL-1 drug | Initial dosage | Maintenance dosage | Duration (days) | Adjuvant corticosteroids | Reduction/withdrawal of corticosteroids | Initial efficacy | Short-term efficacya | Medium/long-term efficacyb | Clinical efficacy | Analytical efficacy | Recurrence | Adverse events |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Anakinra | 1 mg/kg/24 h | (1) | 350 | Yes | Withdrawal | Yes | Yes | Yes | Yes | Yes | Yes | Aggregate data |
| #2 | Anakinra | 1 mg/kg/24 h | (1) | 1500 | Yes | Withdrawal | Yes | Yes | Yes | Yes | Yes | Yes | Aggregate data |
| #3 | Anakinra | 1 mg/kg/24 h | (1) | 40 | Yes | Withdrawal | Yes | Yes | NA | Yes | Yes | Yes | Aggregate data |
| #4 | Anakinra | 1 mg/kg/24 h | (1) | 14 | Yes | Withdrawal | Yes | Yes | NA | Yes | Yes | Yes | Aggregate data |
| #5 | Anakinra | 1 mg/kg/24 h | (1) | 30 | Yes | Withdrawal | Yes | Yes | NA | Yes | Yes | Yes | Aggregate data |
| #6 | Anakinra | 1 mg/kg/24 h | (1) | 100 | Yes | Reduction | No | Yes | NA | Yes | No | Yes | Aggregate data |
| #7 | Anakinra | 5 mg/kg/24 h | 2.5 mg/kg/24 h | 180 | No | NA | Yes | Yes | Yes | Yes | Yes | Yes | NA |
| #8 | Anakinra | 1 mg/kg/24 h | 2.5 mg/kg/24 h | Months | Yes | Withdrawal | Yes | Yes | NA | Yes | Yes | Yes | NA |
| #9 | Anakinra | 1 mg/kg/24 h | 3 mg/kg/24 h | Months | Yes | Withdrawal | Yes | Yes | Yes | Yes | Yes | Yes | NA |
| #10 | Anakinra | NA | NA | 180 | Yes | Withdrawal | Yes | Yes | Yes | Yes | Yes | NA | NA |
| #11 | Anakinra | 1 mg/kg/24 h | 1 mg/kg/24 h | 240 | NA | NA | Yes | Yes | Yes | Yes | Yes | NA | None |
| #12 | Anakinra | NA | NA | NA | NA | NA | Yes | NA | NA | Yes | Yes | NA | None |
| #13 | Anakinra | 3 mg/kg/24 h | 3 mg/kg/24 h | 60 | Yes | Withdrawal | Yes | Yes | NA | Yes | Yes | NA | NA |
| #14 | Anakinra | NA | NA | 270 | NA | NA | Yes | Yes | No | Yes | Yes | NA | NA |
| #15 | Anakinra | NA | 6 weeks | NA | NA | NA | Yes | Yes | NA | Yes | Yes | NA | NA |
| #16 | Canakinumab | 150 mg ew 6 weeks | 150 mg ew × 6 weeks | 365 | NA | NA | Yes | Yes | Yes | Yes | Yes | NA | None |
| #17 | Anakinra | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| #18 | Anakinra | 1.5 mg/kg/24 h | (2) | 365 | Yes | Reduction | Yes | Yes | Yes | Yes | Yes | NA | |
| #19 | Canakinumab | 2 mg/kg/ew 4 weeks | 4 mg/kg/ew × 4–6 weeks | NA | NA | NA | no | Yes | NA | Yes | Yes | NA |
Generalized urticarial rash Vomiting and diarrhea |
ew every week
(1) The dosage was increased by 0.5 mg/kg/day at follow-up visits to achieve C-reactive protein less than 0.5 mg/dl and erythrocyte sedimentation rate less than 15 mm/h
(2) Reduced dosage because of generalized urticarial rash
a < 12 weeks
b > 24 weeks